Around 30% of dogs with idiopathic epilepsy will require lifelong treatment with two or more drugs to control their epilepsy and are thus affected with drug-resistant epilepsy. These drug-resistant epileptic patients often experience substantial side effects and a decreased quality of life for them and their caregivers. Patients with drug resistance are not easily identified early in the course of epilepsy, which could delay the management of their refractory epilepsy.

In this webinar, we will review research exploring biomarkers to predict the potential development of drug resistance in newly diagnosed idiopathic epileptic dogs. By developing an accurate prediction model, veterinarians will be able to individualize and optimize the management of drug-resistant epilepsy through earlier detection of these patients and better defining their prognosis.

This program has been RACE approval for 1 hour of continuing education credit in jurisdictions which recognize RACE approval.